We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc
MRNS

Delisted

MRNS was delisted on the 10th of February, 2025.

Back to rankings

90 hedge funds and large institutions have $98.4M invested in Marinus Pharmaceuticals, Inc in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 23 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more call options, than puts

Call options by funds: $6.41M | Put options by funds: $2.13M

22% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

6% less funds holding

Funds holding: 96 → 90 (-6)

20% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 30

65% less capital invested

Capital invested by funds: $279M → $98.4M (-$180M)

Holders
90
Holders Change
-6
Holders Change %
-6.25%
% of All Funds
2.01%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
24
Increased
28
Reduced
23
Closed
30
Calls
$6.41M
Puts
$2.13M
Net Calls
+$4.27M
Net Calls Change
-$5.77M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$13.4M
2
JG
Jefferies Group
New York
+$8.6M
3
GPCM
Granite Point Capital Management
Massachusetts
+$8.09M
4
Goldman Sachs
Goldman Sachs
New York
+$7.42M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$5.39M

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$10.3M
2
PA
Perceptive Advisors
New York
-$9.08M
3
PHS
PFM Health Sciences
California
-$6.32M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.09M
5
CAM
Cormorant Asset Management
Massachusetts
-$3M
Name Holding Trade Value Shares
Change 		Change in
Stake
CM
26
Caption Management
Oklahoma
$487K -$93.6K -4,625 -10%
TCIM
27
TIAA CREF Investment Management
New York
$430K -$7.2K -356 -0.9%
EGM
28
Engineers Gate Manager
New York
$429K +$756K +37,362 New
SIM
29
Spark Investment Management
New York
$417K +$736K +36,375 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$302K -$26.2K -1,297 -5%
AGM
31
Alpine Global Management
New York
$256K +$451K +22,274 New
UBS Group
32
UBS Group
Switzerland
$246K +$1.76K +87 +0.4%
TA
33
Teachers Advisors
New York
$239K +$71.6K +3,538 +20%
Charles Schwab
34
Charles Schwab
California
$223K – – –
Simplex Trading
35
Simplex Trading
Illinois
$223K +$266K +13,155 +208%
BCM
36
Bridgeway Capital Management
Texas
$206K -$202K -10,000 -36%
MWNA
37
Marshall Wace North America
New York
$195K +$344K +16,995 New
CC
38
Caxton Corporation
New Jersey
$176K +$209K +10,316 +204%
Morgan Stanley
39
Morgan Stanley
New York
$161K -$15K -740 -5%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$160K – – –
Two Sigma Advisers
41
Two Sigma Advisers
New York
$146K +$256K +12,675 New
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$138K +$80K +3,954 +49%
QSS
43
Quantitative Systematic Strategies
Florida
$138K +$243K +11,994 New
Deutsche Bank
44
Deutsche Bank
Germany
$135K -$205K -10,135 -46%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$120K -$63K -3,112 -23%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$109K – – –
JP Morgan Chase
47
JP Morgan Chase
New York
$108K -$392K -19,358 -67%
AIM
48
Alambic Investment Management
California
$106K +$186K +9,200 New
Tudor Investment Corp
49
Tudor Investment Corp
Connecticut
$103K +$182K +9,002 New
AllianceBernstein
50
AllianceBernstein
Tennessee
$81K – – –
1
2
3 4 5

MRNS Hedge Fund Activity: Q4 2018 in Review

90 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2018, worth a combined $98.4M — down 65% from $279M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of MRNS and 24 opened new positions — a net loss of 6 holders — while 23 trimmed existing stakes and 28 added.

The largest buyer was Jennison Associates, adding an estimated $13.4M. The largest seller was Credit Suisse, exiting entirely with an estimated $10.3M sold.

  • 90 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2018, down from 96 in Q3 2018.
  • Funds reported $98.4M of Marinus Pharmaceuticals, Inc stock for Q4 2018, down 65% quarter-over-quarter.
  • 24 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2018 and 30 closed out, a net change of -6 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q4 2018 was Jennison Associates, an estimated $13.4M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q4 2018 was Credit Suisse, an estimated $10.3M sold.

Based on aggregated 13F filings for Q4 2018.